Cerebrospinal Fluid MicroRNA Signatures As Diagnostic Biomarkers in Brain Tumors
Overview
Authors
Affiliations
Central nervous system (CNS) malignancies include primary tumors that originate within the CNS as well as secondary tumors that develop as a result of metastatic spread. Circulating microRNAs (miRNAs) were found in almost all human body fluids including cerebrospinal fluid (CSF), and they seem to be highly stable and resistant to even extreme conditions. The overall aim of our study was to identify specific CSF miRNA patterns that could differentiate among brain tumors. These new biomarkers could potentially aid borderline or uncertain imaging results onto diagnosis of CNS malignancies, avoiding most invasive procedures such as stereotactic biopsy or biopsy. In total, 175 brain tumor patients (glioblastomas, low-grade gliomas, meningiomas and brain metastases), and 40 non-tumor patients with hydrocephalus as controls were included in this prospective monocentric study. Firstly, we performed high-throughput miRNA profiling (Illumina small RNA sequencing) on a discovery cohort of 70 patients and 19 controls and identified specific miRNA signatures of all brain tumor types tested. Secondly, validation of 9 candidate miRNAs was carried out on an independent cohort of 105 brain tumor patients and 21 controls using qRT-PCR. Based on the successful results of validation and various combination patterns of only 5 miRNA levels (miR-30e, miR-140, let-7b, mR-10a and miR-21-3p) we proposed CSF-diagnostic scores for each tumor type which enabled to distinguish them from healthy donors and other tumor types tested. In addition to this primary diagnostic tool, we described the prognostic potential of the combination of miR-10b and miR-196b levels in CSF of glioblastoma patients. In conclusion, we performed the largest study so far focused on CSF miRNA profiling in patients with brain tumors, and we believe that this new class of biomarkers have a strong potential as a diagnostic and prognostic tool in these patients.
Biomarkers in Cerebrospinal Fluid for the Diagnosis and Monitoring of Gliomas.
Papadimitrakis D, Perdikakis M, Gargalionis A, Papavassiliou A Biomolecules. 2024; 14(7).
PMID: 39062515 PMC: 11274947. DOI: 10.3390/biom14070801.
Ordonez-Rubiano E, Rincon-Arias N, Espinosa S, Shelton W, Salazar A, Combita A Curr Res Pharmacol Drug Discov. 2024; 7:100193.
PMID: 39055532 PMC: 11268206. DOI: 10.1016/j.crphar.2024.100193.
Metcalf G Oncogene. 2024; 43(28):2135-2142.
PMID: 38839942 PMC: 11226400. DOI: 10.1038/s41388-024-03076-3.
Innovation in Non-Invasive Diagnosis and Disease Monitoring for Meningiomas.
Korte B, Mathios D Int J Mol Sci. 2024; 25(8).
PMID: 38673779 PMC: 11050588. DOI: 10.3390/ijms25084195.
Joshi R, Sharma A, Kulshreshtha R Mol Ther Oncol. 2024; 32(1):200782.
PMID: 38596289 PMC: 10951709. DOI: 10.1016/j.omton.2024.200782.